Authors
Bobykin E.V., Korotkikh S.A., Morozova O.V., Akimenko I.A.
Ural State Medical University, Yekaterinburg
Abstract
Intravitreal administration of drugs is a widespread method of drug delivery, without which it is impossible to imagine modern ophthalmology. In the Russian Federation, this route of administration is registered for five drugs: ranibizumab, aflibercept, brolucizumab, dexamethasone (implant) and prourokinase. It is known that intravitreal administration of drugs is associated with a number of possible side effects, of which inflammatory adverse events, including sterile intraocular inflammation, brolucizumab-associated retinovasculitis, and post-injection infectious endophthalmitis, have attracted the greatest interest in recent years. The ubiquity of intravitreal injections, primarily associated with the development of anti-VEGF therapy, which in most cases involves frequent repeated procedures, increases the possibility that not only retinal specialists, but also outpatient doctors may face inflammatory complications. For successful treatment of intraocular inflammation, the ophthalmologist must be well versed in its clinical manifestations and existing therapeutic approaches. This review provides a brief description of the various forms of inflammatory adverse events associated with intravitreal drug administration and discusses some of the distinguishing features of these conditions.
Keywords: intravitreal injection, intraocular inflammation, vascular endothelial growth factor, brolucizumab, ranibizumab, aflibercept, uveitis, endophthalmitis, retinovasculitis.
References
1. Xu M, Fan R, Fan X, et al. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. Drug Des Devel Ther. 2022 Sep 22;16:3241-3262. DOI: 10.2147/DDDT.S383101.
2. Файзрахманов Р.Р. Анти-VEGF терапия неоваскулярной возрастной макулярной дегенерации: от рандомизированных исследований к реальной клинической практике // Российский офтальмологический журнал. — 2019. — Т. 12. — № 2. — С. 97-105. [Fayzrakhmanov RR. Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice. Russian Ophthalmological Journal. 2019;12(2):97-105. (In Russ.).] DOI: 10.21516/2072-0076-2019-12-2-97-105.
3. Бобыкин Е.В., Морозова О.В., Береснева Н.С. Лечение заболеваний макулы: резюме ключевых рандомизированных клинических исследований // Российский офтальмологический журнал. — 2021. — Т.14. — № 4. — С. 137-148. [Bobykin E.V., Morozova O.V., Beresneva N.S. Treatment of macular diseases: an overview of key randomized clinical trials. Russian ophthalmological journal. 2021;14(4):137-148 (In Russ.).] DOI: 10.21516/2072-0076-2021-14-4-137-148
4. National Library of Medicine. PubMed.gov. Available from: https://pubmed.ncbi.nlm.nih.gov/?term=intraocular+inflammation+anti+%2B+VEGF&filter=simsearch1.fha&filter=simsearch3.fft.
5. National Library of Medicine. PubMed.gov. Available from: https://pubmed.ncbi.nlm.nih.gov/?term=retinal%20vasculitis%20%20%20anti-VEGF&filter=simsearch1.{fha&filter=simsearch3.fft&timeline=expanded.
6. Gosudarstvennyj reestr lekarstvennyh sredstv. https://grls.rosminzdrav.ru/Default.aspx
7. Fursova AZh, Zabanova VE, Gamza YuA, et al. Ophthalmic safety profile of antiangiogenic therapy. Vestnik Oftalmologii. 2021;137(2):114 122. (In Russ.) DOI: 10.17116/oftalma2021137021114.
8. Loskutov I.A., Kovrizhkina A.A., Andryuhina O.M. Modern concept of a new group of retinal vasculitis. Russian Ophthalmological Journal. 2021; 14(4):149-153. (In Russ.) DOI: 10.21516/2072-0076-2021-14-4-149-153.
9. Kovalevskaya MA, Pererva OA, Roldugin AA, et al. Potential pitfalls of anti-VEGF therapy of neovascular age-related macular degeneration. Vestnik Oftalmologii. 2021;137(6):149-156. (In Russ.) DOI: 10.17116/oftalma2021137061149.
10. Drozdova E.A., Zajceva O.V., Kuznecova T.I., et al. Neinfekcionnoe vnutriglaznoe vospalenie na fone intravitreal’nogo vvedenija lekarstvennogo preparata. Posobie dlja vrachej-oftal’mologov. — Moscow: OOO «Novartis Farma»; 2021. (In Russ.)
11. Cox JT, Eliott D, Sobrin L. Inflammatory Complications of Intravitreal Anti-VEGF Injections. J Clin Med. 2021;10(5):981. doi: 10.3390/jcm10050981.
12. Anderson WJ, da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retin Vitr. 2021;7:37. DOI: 10.1186/s40942-021-00307-7.
13. Post-marketing data in patients with wet AMD and DME. Available from: https://www.brolucizumab.info/ post-marketing-data
14. Astakhov YS, Belekhova SG, Litvinova EA. Infectious and sterile endophthalmitis after intravitreal injections: differential diagnosis, prevention, treatment. Ophthalmology Journal. 2017;10(1):62-69. (In Russ). DOI:10.17816/ OV10162-69.
15. Khanani AM, Cohen GL, Zawadzki R. A Prospective Masked Clinical Assessment of Inflammation After Intravitreal Injection of Ranibizumab or Aflibercept. J Ocul Pharmacol Ther. 2016;32(4):216-218. DOI: 10.1089/jop.2015.0152.
16. Bobykin EV. Silicone oil droplets in the vitreous after intravitreal injections: review of literature with clinical examples. Ophthalmology Journal. 2021;14(2):63-76. (In Russ).]DOI: 10.17816/OV59959.
17. Bobykin EV, Kulakova IA, Morozova OV, et al. Evaluation of the prevalence of silicone oil droplets in the vitreous in patients treated with multiple intravitreal drug injections. Acta biomedica scientifica. 2021; 6(5):126-135. (In Russ). DOI: 10.29413/ABS.2021-6.5.12.
18. Melo GB, Dias Junior CS, Morais FB, et al. Prevalence of silicone oil droplets in eyes treated with intravitreal injection. Int J Retin Vitr. 2019;5:34. DOI: 10.1186/s40942-019-0184-9.
19. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050-1059. DOI: 10.1016/j.ophtha.2020.11.011.
20. Mukai R, Matsumoto H, Akiyama H. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS One. 2021;16(12):e0259879. DOI: 10.1371/journal.pone.0259879.
21. Hoshino J, Matsumoto H, Mukai R, et al. Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization: Comparison of short-term outcomes. Ophthalmologica. Forthcoming 2022. DOI: 10.1159/000526044.
